|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 192 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Allergic Rhinitis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Allergic Rhinitis
- Allergic Rhinitis Therapeutics under Development by Companies
- Allergic Rhinitis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Allergic Rhinitis Therapeutics – Products under Development by Companies
- Allergic Rhinitis Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Allergic Rhinitis Therapeutics Development
- Johnson & Johnson
- Bausch & Lomb Incorporated
- Shionogi & Co., Ltd.
- GlaxoSmithKline plc
- Genentech, Inc.
- Nektar Therapeutics
- MedImmune LLC
- Merck & Co., Inc.
- Dainippon Sumitomo Pharma Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Nycomed International Management GmbH
- Novartis AG
- ALK-Abello A/S
- Meda AB
- Ono Pharmaceutical Co., Ltd.
- Zeria Pharmaceutical Co Ltd
- Sun Pharmaceutical Industries Limited
- Capnia, Inc.
- Nuvo Research Inc.
- Yuhan Corporation
- Stallergenes S.A.
- GenMont Biotech Inc.
- Verona Pharma Plc
- Allergopharma Joachim Ganzer KG
- Palau Pharma S.A
- Respiratorius AB
- Oxagen Limited
- Vantia Therapeutics
- VentiRx Pharmaceuticals, Inc.
- Adamis Pharmaceuticals Corporation
- Laboratorios LETI S.L.
- Morria Biopharmaceuticals Plc
- Viromed Co., Ltd.
- Afexa Life Sciences Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Lipocine Inc.
- Biomay AG
- Indigene Pharmaceuticals, Inc.
- Eurofarma
- Allergic Rhinitis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- DSP-3025 - Drug Profile
- DSP-3025 - Drug Profile
- Bepomax - Drug Profile
- OMNARIS HFA MDI - Drug Profile
- NKTR-125 - Drug Profile
- MLN6095 - Drug Profile
- OX-NLA - Drug Profile
- OC000459 - Drug Profile
- RPL554 - Drug Profile
- NAIPs - Drug Profile
- VA118020 - Drug Profile
- MRX4 - Drug Profile
- VAK-694 - Drug Profile
- Nasal Carbon Dioxide - Drug Profile
- QAX-576 - Drug Profile
- VTX-1463 - Drug Profile
- Z-207 - Drug Profile
- Cold-FX - Drug Profile
- Glycerinated German Cockroach Allergenic Extract - Drug Profile
- Leucet - Drug Profile
- S-555739 - Drug Profile
- Mitizax - Drug Profile
- ACTAIR - Drug Profile
- WF10 - Drug Profile
- GSK685698 - Drug Profile
- UR-63325 - Drug Profile
- Olea Europaea Pollen Extract - Drug Profile
- VAK-694 + Alutard Avanz SQ - Drug Profile
- JNJ-38224342 - Drug Profile
- Modified Allergen Extract - Drug Profile
- QAV-680 + Cetirizine - Drug Profile
- Allergen Extract - Drug Profile
- Mometasone Furoate + Oxymetazoline - Drug Profile
- Depigoid Birch - Drug Profile
- RG7449 - Drug Profile
- Beclomethasone - Drug Profile
- CR-2039 - Drug Profile
- gpASIT + TM - Drug Profile
- AL0701rP - Drug Profile
- RV-568 - Drug Profile
- eN-Lac capsules - Drug Profile
- PG-102 - Drug Profile
- SUN 1334 H - Drug Profile
- SUN 1334 H - Drug Profile
- Bepasone - Drug Profile
- Ragweed Sublingual Immunotherapy Tablet - Drug Profile
- Alutard SQ - Drug Profile
- BM32 - Drug Profile
- ONO-4053 - Drug Profile
- Mometasone Furoate - Drug Profile
- RESP-1100 - Drug Profile
- OC002417 - Drug Profile
- Bilastine - Drug Profile
- TBS-6 - Drug Profile
- BI 144807 - Drug Profile
- HCP1102 - Drug Profile
- HCP0703 - Drug Profile
- APC-3000 - Drug Profile
- MEDI4212 - Drug Profile
- GSK2245035 - Drug Profile
- Sun 0597 Nasal Formulation - Drug Profile
- Sun 0597 Inhalation Formulation - Drug Profile
- Sun 0597 Topical Formulation - Drug Profile
- Sun 0597 Ophthalmic Formulation - Drug Profile
- GE2 - Drug Profile
- Allergic Rhinitis Therapeutics – Drug Profile Updates
- Allergic Rhinitis Therapeutics – Discontinued Products
- Allergic Rhinitis Therapeutics - Dormant Products
- Allergic Rhinitis – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Allergic Rhinitis, H2 2012
- Products under Development for Allergic Rhinitis – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Development by Companies, H2 2012 (Contd..3)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Development by Companies, H2 2012 (Contd..3)
- Products under Development by Companies, H2 2012 (Contd..4)
- Products under Investigation by Universities/Institutes, H2 2012
- Johnson & Johnson, H2 2012
- Bausch & Lomb Incorporated, H2 2012
- Shionogi & Co., Ltd., H2 2012
- GlaxoSmithKline plc, H2 2012
- Genentech, Inc., H2 2012
- Nektar Therapeutics, H2 2012
- MedImmune LLC, H2 2012
- Merck & Co., Inc., H2 2012
- Dainippon Sumitomo Pharma Co., Ltd., H2 2012
- Takeda Pharmaceutical Company Limited, H2 2012
- Nycomed International Management GmbH, H2 2012
- Novartis AG, H2 2012
- ALK-Abello A/S, H2 2012
- Meda AB, H2 2012
- Ono Pharmaceutical Co., Ltd., H2 2012
- Zeria Pharmaceutical Co Ltd, H2 2012
- Sun Pharmaceutical Industries Limited, H2 2012
- Capnia, Inc., H2 2012
- Nuvo Research Inc., H2 2012
- Yuhan Corporation, H2 2012
- Stallergenes S.A., H2 2012
- GenMont Biotech Inc., H2 2012
- Verona Pharma Plc, H2 2012
- Allergopharma Joachim Ganzer KG, H2 2012
- Palau Pharma S.A, H2 2012
- Respiratorius AB, H2 2012
- Oxagen Limited, H2 2012
- Vantia Therapeutics, H2 2012
- VentiRx Pharmaceuticals, Inc., H2 2012
- Adamis Pharmaceuticals Corporation, H2 2012
- Laboratorios LETI S.L., H2 2012
- Morria Biopharmaceuticals Plc, H2 2012
- Viromed Co., Ltd., H2 2012
- Afexa Life Sciences Inc., H2 2012
- Boehringer Ingelheim Pharmaceuticals, Inc., H2 2012
- Lipocine Inc., H2 2012
- Biomay AG, H2 2012
- Indigene Pharmaceuticals, Inc., H2 2012
- Eurofarma, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Allergic Rhinitis Therapeutics – Drug Profile Updates
- Allergic Rhinitis Therapeutics – Discontinued Products
- Allergic Rhinitis Therapeutics – Discontinued Products (Contd..1)
- Allergic Rhinitis Therapeutics – Dormant Products
- Allergic Rhinitis Therapeutics – Dormant Products (Contd..1)
- Allergic Rhinitis Therapeutics – Dormant Products (Contd..2)
- Allergic Rhinitis Therapeutics – Dormant Products (Contd..3)
- Allergic Rhinitis Therapeutics – Dormant Products (Contd..4)
- List of Figures
- Number of Products under Development for Allergic Rhinitis, H2 2012
- Products under Development for Allergic Rhinitis – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractAllergic Rhinitis – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Allergic Rhinitis - Pipeline Review, H2 2012', provides an overview of the Allergic Rhinitis therapeutic pipeline. This report provides information on the therapeutic development for Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Rhinitis. 'Allergic Rhinitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Allergic Rhinitis.
- A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Allergic Rhinitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Allergic Rhinitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
